InsiderSignalSign in
← Insider buys

BAKER BROS. ADVISORS LP has bought stock on 65 days since Jan 2016

Director at Kodiak Sciences Inc., and 28 other companies

SEC CIK 0001263508 · Filings on SEC.gov ↗

$2.8BBought
$1.6BSold
Sep 30Last buy

BAKER BROS. ADVISORS LP's record

3 months after each buy, from the first price a copier could get.

+14.2%Average
+13.8 ptsVs S&P 500
12 of 22Higher

22 buys since 2016 with 3 months of prices.

Companies

Every filing

114 filings since Jan 2016, newest first

KODBuy

Kodiak Sciences Inc.

Director

$63.4M+3.7%Sep 30
KODBuy

Kodiak Sciences Inc.

Director

$35.0M+2.2%Sep 30
KODBuy

Kodiak Sciences Inc.

Director

$58.6M+4.4%Sep 30
CELCSell

Celcuity Inc.

Former 10% owner

$317.8M−41.5%Jul 16
ONCSell

BeOne Medicines Ltd.

Director

$262K−7.2%May 27
KODBuy

Kodiak Sciences Inc.

Director and 10% owner

$60.0M+17.0%Dec 19
KYMRBuy

Kymera Therapeutics, Inc.

Director and 10% owner

$172.5M+34.0%Dec 11
TRDABuy

Entrada Therapeutics, Inc.

10% owner

$262K+1.0%Nov 24
CELCBuy

Celcuity Inc.

10% owner

$9.6M+2.0%Sep 10
MDGLBuy

Madrigal Pharmaceuticals, Inc.

Director

$36.9M+5.0%Aug 20
KYMRBuy

Kymera Therapeutics, Inc.

Director

$28.8M+12.0%Jun 30
IMCRBuy

Immunocore Holdings Plc

Director

$24.0M+60.0%Mar 19
KALABuy

Kala Bio, Inc.

10% owner

$2.0M+40.0%Dec 31
BCYCBuy

Bicycle Therapeutics Plc

Director and 10% owner

$21.2M+17.0%Dec 17
IGMSBuy

Igm Biosciences, Inc.

Director and 10% owner

$3.4M+19.0%Dec 15
MDGLBuy

Madrigal Pharmaceuticals, Inc.

Director

$22.5M+6.0%Dec 14
MDGLBuy

Madrigal Pharmaceuticals, Inc.

Director

$7.5M+2.0%Dec 14
BCELSell

Atreca, Inc.

Former 10% Owner

$111K−8.0%Oct 23
NLTXBuy

Neoleukin Therapeutics, Inc.

Director and 10% owner

$1.5M+69.0%Aug 17
KODBuy

Kodiak Sciences Inc.

Director and 10% owner

$4.4M+4.0%Jun 6
TRDABuy

Entrada Therapeutics, Inc.

10% owner

$261K+1.0%Jun 6
TCRXBuy

Tscan Therapeutics, Inc.

Director and 10% owner

$2.6M+116.0%May 12
INCYBuy

Incyte Corp

Director and 10% owner

$28.1M+1.0%Mar 10
INCYBuy

Incyte Corp

Director and 10% owner

$35.7M+2.0%Feb 22
KODBuy

Kodiak Sciences Inc.

Director and 10% owner

$21.8M+3.0%Feb 17
KODBuy

Kodiak Sciences Inc.

Director and 10% owner

$18.1M+2.0%Jan 31
KODBuy

Kodiak Sciences Inc.

Director and 10% owner

$28.8M+3.0%Jan 25
SGENSell

Seagen Inc.

Director and 10% owner

$63.4M−1.0%Dec 2
TLISBuy

Talis Biomedical Corp

Director and 10% owner

$218K+1.0%Nov 19
KODBuy

Kodiak Sciences Inc.

Director and 10% owner

$8.3M+1.0%Oct 1
KODBuy

Kodiak Sciences Inc.

Director and 10% owner

$3.0MSep 17
KODBuy

Kodiak Sciences Inc.

Director and 10% owner

$5.4MSep 9
KODBuy

Kodiak Sciences Inc.

Director and 10% owner

$10.0M+1.0%Aug 19
KODBuy

Kodiak Sciences Inc.

Director and 10% owner

$9.0M+1.0%Aug 13
TLISBuy

Talis Biomedical Corp

Director and 10% owner

$100.0M+829.0%Feb 19
BGNESell

Beigene, Ltd.

Director and 10% owner

$26.7M−1.0%Jan 6
NLTXBuy

Neoleukin Therapeutics, Inc.

Director

$6.5M+14.0%Dec 23
BGNESell

Beigene, Ltd.

Director and 10% owner

$333.3M−12.0%Dec 4
KODBuy

Kodiak Sciences Inc.

Director and 10% owner

$15.3M+3.0%Sep 8
KODBuy

Kodiak Sciences Inc.

Director and 10% owner

$9.8M+2.0%Aug 21
SGENSell

Seattle Genetics Inc /wa

Director and 10% owner

$280.0M−4.0%May 19
SGENSell

Seattle Genetics Inc /wa

Director and 10% owner

$171.3M−2.0%May 8
ALXNBuy

Alexion Pharmaceuticals, Inc.

Director

$32.8M+6.0%Mar 18
ALXNBuy

Alexion Pharmaceuticals, Inc.

Director

$6.7M+1.0%Mar 18
KODBuy

Kodiak Sciences Inc.

Director and 10% owner

$5.9M+1.0%Mar 18
ACADBuy

Acadia Pharmaceuticals Inc

Director and 10% owner

$33.7M+3.0%Mar 18
KODBuy

Kodiak Sciences Inc.

Director and 10% owner

$87.5M+23.0%Dec 6
AQXPBuy

Aquinox Pharmaceuticals, Inc

Director and 10% owner

$1.1M+4.0%Aug 8
ALXNSell

Alexion Pharmaceuticals, Inc.

Director

$37.1M−4.0%May 30
HOOKBuy

Hookipa Pharma Inc.

Former 10% owner

$12.5M−1238.0%Apr 23
Older filings
About BAKER BROS. ADVISORS LP

BAKER BROS. ADVISORS LP is a hedge fund and investment advisory firm specializing in fundamentally driven investments in the life sciences and biotechnology sectors.( Founded in 2000 and based in New York, NY, the firm operates as the core investment manager of Baker Brothers Investments, managing concentrated portfolios of healthcare and biotech equities for institutional and other sophisticated investors.( Its portfolio managers include Julian and Felix Baker, who oversee a large, research-intensive investment strategy focused on pharmaceutical, biotechnology, and related health services companies.(

As a significant institutional investor, Baker Bros. Advisors LP files regular ownership and insider trading reports with the U.S. Securities and Exchange Commission and is frequently reported as a corporate insider due to its substantial positions and board-level involvement at various biotech companies.( In its most recent filings, the firm reported a multi‑billion‑dollar U.S. equity portfolio with top holdings in companies such as Incyte Corporation, BeOne Medicines AG / BeOne Medicines Ltd. (ONC), Madrigal Pharmaceuticals, Insmed, and ACADIA Pharmaceuticals, reflecting its deep specialization in therapeutics and life sciences.(

Written by Perplexity from public sources.

Filings come from SEC EDGAR. Not investment advice.